Literature DB >> 22692960

Inhibition of Akt potentiates 2-DG-induced apoptosis via downregulation of UPR in acute lymphoblastic leukemia.

Joanna DeSalvo1, Jeffim N Kuznetsov, Jianfeng Du, Gilles M Leclerc, Guy J Leclerc, Theodore J Lampidis, Julio C Barredo.   

Abstract

The ability to pair the regulation of metabolism and cellular energetics with oncogenes and tumor suppressor genes provides cancer cells with a growth and survival advantage over normal cells. We investigated the mechanism of cell death induced by 2-deoxy-D-glucose (2-DG), a sugar analog with dual activity of inhibiting glycolysis and N-linked glycosylation, in acute lymphoblastic leukemia (ALL). We found that, unlike most other cancer phenotypes in which 2-DG only inhibits cell proliferation under normoxic conditions, ALL lymphoblasts undergo apoptosis. Bp-ALL cell lines and primary cells exhibited sensitivity to 2-DG, whereas T-ALL cells were relatively resistant, revealing phenotypic differences within ALL subtypes. Cotreatment with D-mannose, a sugar essential for N-linked glycosylation, rescues 2-DG-treated ALL cells, indicating that inhibition of N-linked glycosylation and induction of ER stress and the unfolded protein response (UPR) is the predominant mechanism of 2-DG's cytotoxicity in ALL. 2-DG-treated ALL cells exhibit upregulation of P-AMPK, P-Akt, and induction of ER stress/UPR markers (IRE1α, GRP78, P-eIF2α, and CHOP), which correlate with PARP cleavage and apoptosis. In addition, we find that pharmacologic and genetic Akt inhibition upregulates P-AMPK, downregulates UPR, and sensitizes ALL cells to remarkably low doses of 2-DG (0.5 mmol/L), inducing 85% cell death and overcoming the relative resistance of T-ALL. In contrast, AMPK knockdown rescues ALL cells by upregulating the prosurvival UPR signaling. Therefore, 2-DG induces ALL cell death under normoxia by inducing ER stress, and AKT and AMPK, traditionally thought to operate predominantly on the glycolytic pathway, differentially regulate UPR activity to determine cell death or survival. Mol Cancer Res; 10(7); 969-78. ©2012 AACR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22692960     DOI: 10.1158/1541-7786.MCR-12-0125

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  29 in total

1.  Low-after-high glucose down-regulated Cx43 in H9c2 cells by autophagy activation via cross-regulation by the PI3K/Akt/mTOR and MEK/ERK1/2 signal pathways.

Authors:  Yaguang Bi; Guangyu Wang; Xiangdong Liu; Meng Wei; Qingyong Zhang
Journal:  Endocrine       Date:  2017-02-08       Impact factor: 3.633

2.  Synergistic increase in efficacy of a combination of 2-deoxy-D-glucose and cisplatin in normoxia and hypoxia: switch from autophagy to apoptosis.

Authors:  Akansha Jalota; Mukesh Kumar; Bhudev C Das; Ajay K Yadav; Kunzang Chosdol; Subrata Sinha
Journal:  Tumour Biol       Date:  2016-06-15

3.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

4.  Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.

Authors:  Guy J Leclerc; Joanna DeSalvo; Jianfeng Du; Ningguo Gao; Gilles M Leclerc; Mark A Lehrman; Theodore J Lampidis; Julio C Barredo
Journal:  Leuk Res       Date:  2015-08-20       Impact factor: 3.156

Review 5.  Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities.

Authors:  Ali Khateb; Ze'ev A Ronai
Journal:  Trends Cancer       Date:  2020-06-13

Review 6.  ER Stress and Unfolded Protein Response in Leukemia: Friend, Foe, or Both?

Authors:  Kelly Féral; Manon Jaud; Céline Philippe; Doriana Di Bella; Stéphane Pyronnet; Kevin Rouault-Pierre; Laurent Mazzolini; Christian Touriol
Journal:  Biomolecules       Date:  2021-01-30

Review 7.  Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets.

Authors:  Takahiko Murayama; Noriko Gotoh
Journal:  Cancer Drug Resist       Date:  2019-09-19

8.  The UPR branch IRE1-bZIP60 in plants plays an essential role in viral infection and is complementary to the only UPR pathway in yeast.

Authors:  Lingrui Zhang; Hui Chen; Federica Brandizzi; Jeanmarie Verchot; Aiming Wang
Journal:  PLoS Genet       Date:  2015-04-15       Impact factor: 5.917

9.  Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib.

Authors:  S Jagannathan; M A Y Abdel-Malek; E Malek; N Vad; T Latif; K C Anderson; J J Driscoll
Journal:  Leukemia       Date:  2015-06-25       Impact factor: 11.528

10.  The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.

Authors:  Matteo Allegretti; Maria Rosaria Ricciardi; Roberto Licchetta; Simone Mirabilii; Stefania Orecchioni; Francesca Reggiani; Giovanna Talarico; Roberto Foà; Francesco Bertolini; Sergio Amadori; Maria Rosaria Torrisi; Agostino Tafuri
Journal:  Sci Rep       Date:  2015-12-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.